Intragenic mutations in thyroid cancer.

[1]  S. Nagataki,et al.  Low incidence of the stimulatory G protein alpha-subunit mutations in autonomously functioning thyroid adenomas in Japan. , 2009, Thyroid : official journal of the American Thyroid Association.

[2]  J. Fletcher,et al.  BRAF in Papillary Thyroid Carcinoma of Ovary (Struma Ovarii) , 2007, The American journal of surgical pathology.

[3]  M. Santoro,et al.  Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. , 2007, Thyroid : official journal of the American Thyroid Association.

[4]  M. Xing,et al.  BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. , 2007, The Journal of clinical endocrinology and metabolism.

[5]  Wei Wang,et al.  High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. , 2007, The Journal of clinical endocrinology and metabolism.

[6]  Giovanni Romeo,et al.  Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors , 2007, Proceedings of the National Academy of Sciences.

[7]  T. Takano,et al.  BRAFV600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas , 2007, British Journal of Cancer.

[8]  V. Leite,et al.  Poorly differentiated and anaplastic thyroid carcinomas: chromosomal and oligo-array profile of five new cell lines , 2007, British Journal of Cancer.

[9]  O. Sheils,et al.  BRAF T1799A Mutation Occurring in a Case of Malignant Struma Ovarii , 2007, International journal of surgical pathology.

[10]  N. Matsumoto,et al.  RET oncogene amplification in thyroid cancer: correlations with radiation-associated and high-grade malignancy. , 2007, Human pathology.

[11]  R. Moon,et al.  Overexpression of Wnt-1 in thyrocytes enhances cellular growth but suppresses transcription of the thyroperoxidase gene via different signaling mechanisms. , 2007, The Journal of endocrinology.

[12]  K. Arihiro,et al.  The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation dose , 2007, Molecular carcinogenesis.

[13]  A. El‐Naggar,et al.  Genetic Alterations and Their Relationship in the Phosphatidylinositol 3-Kinase/Akt Pathway in Thyroid Cancer , 2007, Clinical Cancer Research.

[14]  P. Hou,et al.  Functional Characterization of the T1799-1801del and G1799-1816ins BRAF Mutations in Papillary Thyroid Cancer , 2007, Cell cycle.

[15]  Bhuvanesh Singh,et al.  Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression. , 2006, Surgery.

[16]  A. Giuliano,et al.  Lymphatic Mapping Establishes the Role of BRAF Gene Mutation in Papillary Thyroid Carcinoma , 2006, Annals of surgery.

[17]  B. Cho,et al.  Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto‐pathology diagnosis, especially in BRAFV600E mutation‐prevalent area , 2006, Clinical endocrinology.

[18]  Tae Yong Kim,et al.  The BRAF mutation is useful for prediction of clinical recurrence in low‐risk patients with conventional papillary thyroid carcinoma , 2006, Clinical endocrinology.

[19]  X. Qian,et al.  BRAF Mutation Analysis in Fine Needle Aspiration (FNA) Cytology of the Thyroid , 2006, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[20]  R. Seruca,et al.  H-RAS 81 polymorphism is significantly associated with aneuploidy in follicular tumors of the thyroid , 2006, Oncogene.

[21]  V. Trovisco,et al.  B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. , 2006, Human pathology.

[22]  David Wynford-Thomas,et al.  Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant. , 2006, Human pathology.

[23]  O. Bruno,et al.  Follicular carcinoma presenting as autonomous functioning thyroid nodule and containing an activating mutation of the TSH receptor (T620I) and a mutation of the Ki-RAS (G12C) genes. , 2006, Thyroid : official journal of the American Thyroid Association.

[24]  A. Pinchera,et al.  Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. , 2006, Endocrine-related cancer.

[25]  S. Asa,et al.  Pathogenetic mechanisms in thyroid follicular-cell neoplasia , 2006, Nature Reviews Cancer.

[26]  J. Fagin,et al.  Inhibitors of Raf Kinase Activity Block Growth of Thyroid Cancer Cells with RET/PTC or BRAF Mutations In vitro and In vivo , 2006, Clinical Cancer Research.

[27]  M. Santoro,et al.  BRAF Is a Therapeutic Target in Aggressive Thyroid Carcinoma , 2006, Clinical Cancer Research.

[28]  M. Zou,et al.  Association of mitochondrial DNA transversion mutations with familial medullary thyroid carcinoma/multiple endocrine neoplasia type 2 syndrome , 2006, Oncogene.

[29]  G. Troncone,et al.  Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). , 2006, European journal of endocrinology.

[30]  T. Giordano,et al.  Correlation Between Genetic Alterations and Microscopic Features, Clinical Manifestations, and Prognostic Characteristics of Thyroid Papillary Carcinomas , 2006, The American journal of surgical pathology.

[31]  J. Fagin,et al.  BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis. , 2006, Endocrinology.

[32]  N. Rosen,et al.  V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Tartaglia,et al.  Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAFV599Ins) , 2006, Clinical endocrinology.

[34]  P. Workman,et al.  Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. , 2005, Cancer research.

[35]  M. Montani,et al.  No mutations but an increased frequency of SDHx polymorphisms in patients with sporadic and familial medullary thyroid carcinoma. , 2005, Endocrine-related cancer.

[36]  T. Fukushima,et al.  Roles of RAS and BRAF mutations in thyroid carcinogenesis. , 2005, Fukushima journal of medical science.

[37]  P. Ladenson,et al.  BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. , 2005, The Journal of clinical endocrinology and metabolism.

[38]  M. Santoro,et al.  Mutation of the PIK3CA gene in anaplastic thyroid cancer. , 2005, Cancer research.

[39]  Eyal Gottlieb,et al.  Mitochondrial tumour suppressors: a genetic and biochemical update , 2005, Nature Reviews Cancer.

[40]  Tae Yong Kim,et al.  The BRAFV600E mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma , 2005 .

[41]  Yi‐Ju Chen,et al.  No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan , 2005, Clinical endocrinology.

[42]  E. Fonseca,et al.  Molecular pathology of well-differentiated thyroid carcinomas , 2005, Virchows Archiv.

[43]  Guojun Wu,et al.  High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. , 2005, The Journal of clinical endocrinology and metabolism.

[44]  P. Ladenson,et al.  Letter re: uncommon mutation but common amplifications of the PIK3CA gene in thyroid tumors. , 2005, The Journal of clinical endocrinology and metabolism.

[45]  J. Lyons,et al.  Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. , 2005, Current opinion in pharmacology.

[46]  P. Ladenson,et al.  Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. , 2005, The Journal of clinical endocrinology and metabolism.

[47]  J. Franklyn,et al.  Pituitary tumour transforming gene (PTTG) induces genetic instability in thyroid cells , 2005, Oncogene.

[48]  R. Lothe,et al.  Adenomas and follicular carcinomas of the thyroid display two major patterns of chromosomal changes , 2005, The Journal of pathology.

[49]  M. Sobrinho-Simões,et al.  A Subset of the Follicular Variant of Papillary Thyroid Carcinoma Harbors the PAX8-PPARγ Translocation , 2005, International journal of surgical pathology.

[50]  V. Trovisco,et al.  A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma. , 2005, Human pathology.

[51]  P. Gattuso,et al.  Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations , 2005, Cancer.

[52]  V. Trovisco,et al.  Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness , 2005, Virchows Archiv.

[53]  Lei Zhang,et al.  Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. , 2005, Cancer research.

[54]  J. Livezey,et al.  BRAF mutations are uncommon in papillary thyroid cancer of young patients. , 2005, Thyroid : official journal of the American Thyroid Association.

[55]  J. Frost,et al.  B-Raf and Raf-1 Are Regulated by Distinct Autoregulatory Mechanisms* , 2005, Journal of Biological Chemistry.

[56]  Dillwyn Williams,et al.  Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hürthle cell) tumours of the thyroid , 2005, British Journal of Cancer.

[57]  G. Thomas,et al.  Frequency of BRAF T1796A mutation in papillary thyroid carcinoma relates to age of patient at diagnosis and not to radiation exposure , 2005, The Journal of pathology.

[58]  B. Ponder,et al.  Succinate dehydrogenase D variants do not constitute a risk factor for developing C cell hyperplasia or sporadic medullary thyroid carcinoma. , 2005, The Journal of clinical endocrinology and metabolism.

[59]  Y. Nikiforov,et al.  Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to gamma-radiation: a model of carcinogenic chromosomal rearrangement induced by ionizing radiation. , 2005, The Journal of clinical endocrinology and metabolism.

[60]  E. Kimura,et al.  Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched‐lymph node metastasis reveals a new mutation in metastasis , 2005, Clinical endocrinology.

[61]  M. Kruhøffer,et al.  The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. , 2005, The Journal of clinical investigation.

[62]  Q. Duh,et al.  Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. , 2005, Thyroid : official journal of the American Thyroid Association.

[63]  R. Domingues,et al.  Searching for RET/PTC rearrangements and BRAF V599E mutation in thyroid aspirates might contribute to establish a preoperative diagnosis of papillary thyroid carcinoma , 2005, Cytopathology : official journal of the British Society for Clinical Cytology.

[64]  M. Nikiforova,et al.  Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. , 2005, The Journal of clinical investigation.

[65]  E. Fonseca,et al.  Hürthle (Oncocytic) Cell Tumors of Thyroid: Etiopathogenesis, Diagnosis and Clinical Significance , 2005, International journal of surgical pathology.

[66]  W. Giaretti,et al.  Chromosomal Instability, Aneuploidy, and Gene Mutations in Human Sporadic Colorectal Adenomas , 2004, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[67]  H. Namba,et al.  The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma. , 2004, International journal of oncology.

[68]  T. Kurihara,et al.  Immunohistochemical and sequencing analyses of the Wnt signaling components in Japanese anaplastic thyroid cancers. , 2004, Thyroid : official journal of the American Thyroid Association.

[69]  S. Sahin,et al.  Does a Leu 512 Arg thyrotropin receptor mutation cause an autonomously functioning papillary carcinoma? , 2004, Thyroid : official journal of the American Thyroid Association.

[70]  Masahiro Ito,et al.  A Rapid and Simple Detection Method for the BRAFT1796A Mutation in Fine-Needle Aspirated Thyroid Carcinoma Cells , 2004 .

[71]  Y. Nikiforov,et al.  Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. , 2004, The Journal of clinical endocrinology and metabolism.

[72]  Kyung-Hee Kim,et al.  Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. , 2004, Yonsei medical journal.

[73]  M. Gariboldi,et al.  Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer , 2004, Oncogene.

[74]  Masahiro Ito,et al.  Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. , 2004, The Journal of clinical endocrinology and metabolism.

[75]  M. Santoro,et al.  BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. , 2004, The Journal of clinical endocrinology and metabolism.

[76]  P. Beck‐Peccoz,et al.  BRAF mutations in an Italian cohort of thyroid cancers , 2004, Clinical endocrinology.

[77]  L. Sobrinho,et al.  Underexpression of peroxisome proliferator-activated receptor (PPAR)γ in PAX8/PPARγ-negative thyroid tumours , 2004, British Journal of Cancer.

[78]  P. Ladenson,et al.  Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. , 2004, The Journal of clinical endocrinology and metabolism.

[79]  M. Nikiforova,et al.  Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. , 2004, Cancer letters.

[80]  A. Pinchera,et al.  BRAFV599E Mutation Is the Leading Genetic Event in Adult Sporadic Papillary Thyroid Carcinomas , 2004 .

[81]  N. Eberhardt,et al.  The PAX8/PPARγ fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARγ inhibition , 2004, Oncogene.

[82]  V. Trovisco,et al.  BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas , 2004, Virchows Archiv.

[83]  D. Clark,et al.  Mutational Analysis of BRAF in Fine Needle Aspiration Biopsies of the Thyroid: A Potential Application for the Preoperative Assessment of Thyroid Nodules , 2004, Clinical Cancer Research.

[84]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[85]  V. Trovisco,et al.  BRAF mutations are associated with some histological types of papillary thyroid carcinoma , 2004, The Journal of pathology.

[86]  J. Soares,et al.  Chromosomal imbalances associated with anaplastic transformation of follicular thyroid carcinomas , 2004, British Journal of Cancer.

[87]  R. Paschke,et al.  Two somatic TSH receptor mutations in a patient with toxic metastasising follicular thyroid carcinoma and non-functional lung metastases. , 2003, Endocrine-related cancer.

[88]  M. Nikiforova,et al.  BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. , 2003, The Journal of clinical endocrinology and metabolism.

[89]  M. Honavar,et al.  Germline succinate dehydrogenase subunit D mutation segregating with familial non-RET C cell hyperplasia. , 2003, The Journal of clinical endocrinology and metabolism.

[90]  Shinichi Suzuki,et al.  BRAF mutations in papillary carcinomas of the thyroid , 2003, Oncogene.

[91]  K. Guan,et al.  Regulation of Raf through Phosphorylation and N Terminus-C Terminus Interaction* , 2003, Journal of Biological Chemistry.

[92]  T. Dwight,et al.  Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. , 2003, The Journal of clinical endocrinology and metabolism.

[93]  R. Camp,et al.  ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  H. Namba,et al.  Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. , 2003, The Journal of clinical endocrinology and metabolism.

[95]  V. Trovisco,et al.  BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC , 2003, Oncogene.

[96]  A. Fischer,et al.  Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. , 2003, American journal of clinical pathology.

[97]  V. Vasko,et al.  Specific pattern of RAS oncogene mutations in follicular thyroid tumors. , 2003, The Journal of clinical endocrinology and metabolism.

[98]  E. Fonseca,et al.  E‐cadherin loss rather than β‐catenin alterations is a common feature of poorly differentiated thyroid carcinomas , 2003, Histopathology.

[99]  Yuri E Nikiforov,et al.  RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.

[100]  Yuri E Nikiforov,et al.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. , 2003, Cancer research.

[101]  J. Frost,et al.  Phosphorylation of Raf-1 by p21-activated Kinase 1 and Src Regulates Raf-1 Autoinhibition* , 2003, The Journal of Biological Chemistry.

[102]  Guochang Huang,et al.  GRIM‐19, a death‐regulatory gene product, suppresses Stat3 activity via functional interaction , 2003, The EMBO journal.

[103]  J. Soares,et al.  Chromosome imbalances in thyroid follicular neoplasms: A comparison between follicular adenomas and carcinomas , 2003, Genes, chromosomes & cancer.

[104]  K. Chin,et al.  Anaplastic thyroid cancer: cytogenetic patterns by comparative genomic hybridization. , 2003, Thyroid : official journal of the American Thyroid Association.

[105]  Charis Eng,et al.  A role for mitochondrial enzymes in inherited neoplasia and beyond , 2003, Nature Reviews Cancer.

[106]  J. Shah,et al.  Genome-wide appraisal of thyroid cancer progression. , 2002, The American journal of pathology.

[107]  L. Sobrinho,et al.  Expression of PAX8-PPARγ1 Rearrangements in Both Follicular Thyroid Carcinomas and Adenomas , 2002 .

[108]  Dillwyn Williams.  Cancer after nuclear fallout: lessons from the Chernobyl accident , 2002, Nature Reviews Cancer.

[109]  P. Soares,et al.  Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hürthle cell tumors. , 2002, The American journal of pathology.

[110]  E. Fonseca,et al.  Poorly Differentiated Carcinomas of the Thyroid Gland , 2002, International journal of surgical pathology.

[111]  J. Fagin,et al.  Mechanisms of aneuploidy in thyroid cancer cell lines and tissues: evidence for mitotic checkpoint dysfunction without mutations in BUB1 and BUBR1 , 2002, Clinical endocrinology.

[112]  R. Paschke,et al.  Somatic mutations in thyroid nodular disease. , 2002, Molecular genetics and metabolism.

[113]  J. Soares,et al.  Karyotypic characterization of papillary thyroid carcinomas , 2001, Cancer.

[114]  M. Runswick,et al.  GRIM-19, a Cell Death Regulatory Gene Product, Is a Subunit of Bovine Mitochondrial NADH:Ubiquinone Oxidoreductase (Complex I)* , 2001, The Journal of Biological Chemistry.

[115]  C. Peyssonnaux,et al.  The Raf/MEK/ERK pathway: new concepts of activation , 2001, Biology of the cell.

[116]  R. Paschke,et al.  Ras mutations are rare in solitary cold and toxic thyroid nodules , 2001, Clinical endocrinology.

[117]  B. Dörken,et al.  Bax expression in benign and malignant thyroid tumours: Dysregulation of wild‐type P53 is associated with a high Bax and P21 expression in thyroid carcinoma , 2001, International journal of cancer.

[118]  A. Allgeier,et al.  Mutation analysis of the Epac--Rap1 signaling pathway in cold thyroid follicular adenomas. , 2001, European journal of endocrinology.

[119]  M. Sobrinho-Simões,et al.  Somatic but not germline mutation of the APC gene in a case of cribriform-morular variant of papillary thyroid carcinoma. , 2001, American journal of clinical pathology.

[120]  D. Rimm,et al.  β-Catenin Dysregulation in Thyroid Neoplasms : Down-Regulation, Aberrant Nuclear Expression, and CTNNB1 Exon 3 Mutations Are Markers for Aggressive Tumor Phenotypes and Poor Prognosis , 2001 .

[121]  M. Sobrinho-Simões,et al.  Mitochondrial DNA ‘common’ deletion in Hürthle cell lesions of the thyroid , 2000, The Journal of pathology.

[122]  S. Filetti,et al.  A Phe 486 thyrotropin receptor mutation in an autonomously functioning follicular carcinoma that was causing hyperthyroidism. , 2000, Thyroid : official journal of the American Thyroid Association.

[123]  P. Shapiro,et al.  Identification of GRIM-19, a Novel Cell Death-regulatory Gene Induced by the Interferon-β and Retinoic Acid Combination, Using a Genetic Approach* , 2000, The Journal of Biological Chemistry.

[124]  M. Duquenne,et al.  No Evidence of Thyrotropin Receptor and GSα Gene Mutation in High Iodine Uptake Thyroid Carcinoma , 2000 .

[125]  C. J. Chen,et al.  PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. , 2000, Science.

[126]  B. Spiegelman,et al.  PAX8-PPARγ1 Fusion in Oncogene Human Thyroid Carcinoma , 2000 .

[127]  M. Sobrinho-Simões,et al.  Hürthle cell tumours of the thyroid. A review with emphasis on mitochondrial abnormalities with clinical relevance , 2000, Virchows Archiv.

[128]  D. Kalvakolanu,et al.  Chromosomal localization of human GRIM-19, a novel IFN-beta and retinoic acid-activated regulator of cell death. , 2000, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[129]  C. Larsson,et al.  Balanced translocation (3;7)(p25;q34): another mechanism of tumorigenesis in follicular thyroid carcinoma? , 2000, Cancer genetics and cytogenetics.

[130]  A. Pinchera,et al.  Activating thyrotropin receptor mutations are present in nonadenomatous hyperfunctioning nodules of toxic or autonomous multinodular goiter. , 2000, The Journal of clinical endocrinology and metabolism.

[131]  K. Lunetta,et al.  Somatic mitochondrial DNA (mtDNA) mutations in papillary thyroid carcinomas and differential mtDNA sequence variants in cases with thyroid tumours , 2000, Oncogene.

[132]  J W Arends,et al.  Molecular interactions in the Vogelstein model of colorectal carcinoma , 2000, The Journal of pathology.

[133]  A. Pinchera,et al.  Functioning and nonfunctioning thyroid adenomas involve different molecular pathogenetic mechanisms. , 1999, The Journal of clinical endocrinology and metabolism.

[134]  E. Tajara,et al.  Interphase cytogenetic analysis of normal tissue of thyroid gland by fluorescence in situ hybridization. , 1999, Cancer genetics and cytogenetics.

[135]  D. Johnston,et al.  Image analysis of papillary thyroid carcinoma fine‐needle aspirates , 1999 .

[136]  D. Rimm,et al.  Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. , 1999, Cancer research.

[137]  C. Esapa,et al.  Prevalence of Ras mutations in thyroid neoplasia , 1999, Clinical endocrinology.

[138]  F. Cetani,et al.  Genetic analysis of the TSH receptor gene in differentiated human thyroid carcinomas , 1999, Journal of endocrinological investigation.

[139]  J. Chan,et al.  Cribriform-morular variant of papillary carcinoma: a distinctive variant representing the sporadic counterpart of familial adenomatous polyposis-associated thyroid carcinoma? , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[140]  K. Kashima,et al.  Mutations of p53 in thyroid carcinoma with an insular component. , 1999, Thyroid : official journal of the American Thyroid Association.

[141]  M. Sack,et al.  Follicular variant of papillary carcinoma. Cytologic and histologic correlation. , 1999, American journal of clinical pathology.

[142]  R. Feinmesser,et al.  DNA ploidy in papillary carcinoma of the thyroid gland in children and adolescents. , 1998, International journal of pediatric otorhinolaryngology.

[143]  R. Paschke,et al.  The extracellular thyrotropin receptor domain is not a major candidate for mutations in toxic thyroid nodules. , 1998, Thyroid : official journal of the American Thyroid Association.

[144]  M. Risio,et al.  Specific K-ras2 mutations in human sporadic colorectal adenomas are associated with DNA near-diploid aneuploidy and inhibition of proliferation. , 1998, The American journal of pathology.

[145]  K. Franssila,et al.  Comparison of benign and malignant follicular thyroid tumours by comparative genomic hybridization. , 1998, British Journal of Cancer.

[146]  Hong,et al.  Prevalences of Gsα, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population , 1998, Clinical endocrinology.

[147]  D. Segev,et al.  Absence of activating mutations of the genes encoding the alpha-subunits of G11 and Gq in thyroid neoplasia. , 1998, The Journal of clinical endocrinology and metabolism.

[148]  J. Soares,et al.  Cytogenetic investigations of 340 thyroid hyperplasias and adenomas revealing correlations between cytogenetic findings and histology. , 1998, Cancer genetics and cytogenetics.

[149]  G. Chiappetta,et al.  RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[150]  Moore,et al.  Apoptosis in thyroid neoplasms: relationship with p53 and bcl‐2 expression , 1998, Histopathology.

[151]  L. Mariani,et al.  Insular carcinoma: a distinct de novo entity among follicular carcinomas of the thyroid gland. , 1997, The American journal of surgical pathology.

[152]  S. Filetti,et al.  Detection of an activating mutation of the thyrotropin receptor in a case of an autonomously hyperfunctioning thyroid insular carcinoma. , 1997, The Journal of clinical endocrinology and metabolism.

[153]  R. Paschke,et al.  Somatic Mutations in the Thyrotropin Receptor Gene and Not in the Gsα Protein Gene in 31 Toxic Thyroid Nodules1 , 1997 .

[154]  D. Lazzereschi,et al.  Oncogenes and antioncogenes involved in human thyroid carcinogenesis. , 1997, Journal of experimental & clinical cancer research : CR.

[155]  P. Rocmans,et al.  Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas. , 1997, The Journal of clinical endocrinology and metabolism.

[156]  P. Brazzarola,et al.  Heterogeneity of nuclear DNA pattern and its relationship with cell cycle activity parameters in multinodular goitre , 1997, Clinical endocrinology.

[157]  Y. Nikiforov,et al.  Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. , 1997, Cancer research.

[158]  J. Dumont,et al.  Clinical review 84: Thyroid autonomy: mechanism and clinical effects. , 1996, The Journal of clinical endocrinology and metabolism.

[159]  J. Dumont,et al.  Thyroid autonomy: mechanism and clinical effects: clinical review 84 , 1996 .

[160]  J. Fagin,et al.  Structural studies of the thyrotropin receptor and Gs alpha in human thyroid cancers: low prevalence of mutations predicts infrequent involvement in malignant transformation. , 1996, The Journal of clinical endocrinology and metabolism.

[161]  D. Wallace,et al.  Coordinate expression of nuclear and mitochondrial genes involved in energy production in carcinoma and oncocytoma. , 1996, Biochimica et biophysica acta.

[162]  M. Derwahl.  TSH receptor and Gs-alpha gene mutations in the pathogenesis of toxic thyroid adenomas--a note of caution. , 1996, The Journal of clinical endocrinology and metabolism.

[163]  L. Hsieh,et al.  p53 gene mutation in thyroid carcinoma. , 1996, Cancer letters.

[164]  A. de Leiva,et al.  Ras Oncogene Mutations in Thyroid Tumors: Polymerase Chain Reaction‐Restriction‐Fragment‐Length Polymorphism Analysis from Paraffin‐Embedded Tissues , 1996, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[165]  P. Goodfellow,et al.  Infrequent CDKN2 mutation in human differentiated thyroid cancers , 1996, Molecular carcinogenesis.

[166]  N. Ishikawa,et al.  Rarity of oncogenic mutations in the thyrotropin receptor of autonomously functioning thyroid nodules in Japan. , 1995, The Journal of clinical endocrinology and metabolism.

[167]  D. Weghuis,et al.  Detection of numerical alterations for chromosomes 7 and 12 in benign thyroid lesions by in situ hybridization. Histological implications. , 1995, The American journal of pathology.

[168]  S. Swillens,et al.  Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3',5'-monophosphate and inositol phosphate-Ca2+ cascades. , 1995, Molecular endocrinology.

[169]  G. Attardi,et al.  Complementation and segregation behavior of disease-causing mitochondrial DNA mutations in cellular model systems. , 1995, Biochimica et biophysica acta.

[170]  P. Soares,et al.  Recent advances in cytometry, cytogenetics and molecular genetics of thyroid tumours and tumour-like lesions. , 1995, Pathology, research and practice.

[171]  M. Risio,et al.  K-ras-2 G-C and G-T transversions correlate with DNA aneuploidy in colorectal adenomas. , 1995, Gastroenterology.

[172]  S. Filetti,et al.  Genetic alterations in thyroid hyperfunctioning adenomas. , 1995, The Journal of clinical endocrinology and metabolism.

[173]  R. Ashfaq,et al.  Papillary and follicular thyroid carcinomas with an insular component , 1994, Cancer.

[174]  J. Bullerdiek,et al.  A characteristic sequence of trisomies starting with trisomy 7 in benign thyroid tumors , 1994, Human Genetics.

[175]  E. Laurent,et al.  Role of the cyclic adenosine 3',5'-monophosphate and the phosphatidylinositol-Ca2+ cascades in mediating the effects of thyrotropin and iodide on hormone synthesis and secretion in human thyroid slices. , 1994, The Journal of clinical endocrinology and metabolism.

[176]  M. Schlumberger,et al.  Oncogenes and anti-oncogenes in human epithelial thyroid tumors , 1994, Journal of endocrinological investigation.

[177]  M. Zou,et al.  Molecular basis of thyroid cancer. , 1994, Endocrine reviews.

[178]  P. Soares,et al.  Immunohistochemical detection of p53 in differentiated, poorly differentiated and undifferentiated carcinomas of the thyroid , 1994, Histopathology.

[179]  J. Soares,et al.  Deletion of 3p25→pter in a primary follicular thyroid carcinoma and its metastasis , 1993, Genes, chromosomes & cancer.

[180]  J. Parma,et al.  Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas , 1993, Nature.

[181]  M. Zou,et al.  p53 mutations in all stages of thyroid carcinomas. , 1993, The Journal of clinical endocrinology and metabolism.

[182]  T. Seyama,et al.  Genetic Alterations in Thyroid Tumor Progression: Association with p53 Gene Mutations , 1993, Japanese journal of cancer research : Gann.

[183]  T. Oyama,et al.  Overexpression of p53 as a Possible Prognostic Factor in Human Thyroid Carcinoma , 1993, The American journal of surgical pathology.

[184]  M. Pierotti,et al.  Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. , 1993, The Journal of clinical investigation.

[185]  M. Papotti,et al.  Poorly Differentiated Thyroid Carcinomas with Primordial Cell Component: A Group of Aggressive Lesions Sharing Insular, Trabecular,and Solid Patterns , 1993, The American journal of surgical pathology.

[186]  G. Sozzi,et al.  A t(2;3)(q12-13;p24-25) in follicular thyroid adenomas. , 1992, Cancer genetics and cytogenetics.

[187]  T. Seyama,et al.  Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. , 1992, Cancer research.

[188]  N. Lemoine,et al.  Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours. , 1991, Oncogene.

[189]  B. Caillou,et al.  gsp mutations in human thyroid tumours. , 1991, Oncogene.

[190]  T. Mattfeldt,et al.  Stereology, flow cytometry, and immunohistochemistry of follicular neoplasms of the thyroid gland. , 1991, Human pathology.

[191]  N. Matheson,et al.  DNA aneuploidy in follicular thyroid neoplasia , 1991, The British journal of surgery.

[192]  C. Schultz,et al.  Frequent occurrence of cytogenetic abnormalities in sporadic nonmedullary thyroid carcinoma , 1990, Cancer.

[193]  E. Kawasaki,et al.  Two G protein oncogenes in human endocrine tumors. , 1990, Science.

[194]  E. van den Berg,et al.  Cytogenetics of thyroid follicular adenomas. , 1990, Cancer genetics and cytogenetics.

[195]  G. Fleuren,et al.  Frequency and degree of aneuploidy in benign and malignant thyroid neoplasms , 1990, International journal of cancer.

[196]  Joyce Bos.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[197]  H. Bourne,et al.  GTPase inhibiting mutations activate the α chain of Gs and stimulate adenylyl cyclase in human pituitary tumours , 1989, Nature.

[198]  J. Jauniaux,et al.  The cyclic AMP-mediated stimulation of cell proliferation. , 1989, Trends in biochemical sciences.

[199]  H. Joensuu,et al.  DNA aneuploidy in adenomas of endocrine organs. , 1988, The American journal of pathology.

[200]  J. Hrafnkelsson,et al.  A comparative study of DNA cytometry methods for benign and malignant thyroid tissue. , 1988, American journal of clinical pathology.

[201]  K. Christov.  Flow cytometric DNA measurements in human thyroid tumors , 1986, Virchows Archiv. B, Cell pathology including molecular pathology.

[202]  J. Rosai,et al.  Poorly differentiated (“insular”) thyroid carcinoma: A reinterpretation of Langhans' “wuchernde Struma” , 1984, The American journal of surgical pathology.

[203]  P. Soares,et al.  Mitochondria and Oncocytomas , 2009 .

[204]  O. M. Grbovic,et al.  V600E B‐Rafはその安定性にHsp90シャペロンを要求し,Hsp90阻害剤への応答として分解される , 2006 .

[205]  V. Trovisco,et al.  PAX8-PPARγ rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma , 2006 .

[206]  S. Michiels,et al.  Tumorigenesis and Neoplastic Progression Follicular Thyroid Tumors with the PAX 8-PPAR 1 Rearrangement Display Characteristic Genetic Alterations , 2005 .

[207]  N. Eberhardt,et al.  PPARgamma staining as a surrogate for PAX8/PPARgamma fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value. , 2005, The Journal of clinical endocrinology and metabolism.

[208]  P. Gattuso,et al.  Genomic DNA Extraction and PCR Amplification of Exon 15 of the BRAF Gene and Exons 1 and 2 of the NRAS Gene , 2003 .

[209]  A. Gill,et al.  Detection of the PAX8-PPARγ Fusion Oncogene in Both Follicular Thyroid Carcinomas and Adenomas , 2003 .

[210]  G. Chiappetta,et al.  RET activation and clinicopathologic features in poorly differentiated thyroid tumors. , 2002, The Journal of clinical endocrinology and metabolism.

[211]  G. Chiappetta,et al.  Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. , 2002, The American journal of pathology.

[212]  Cdm Fletcher,et al.  World Health Organization Classification of Tumours , 2002 .

[213]  B. Szende,et al.  bcl2, p53 and bax in thyroid tumors and their relation to apoptosis. , 2001, Neoplasma.

[214]  Knut Krohn,et al.  Detection of thyroid-stimulating hormone receptor and Gsα mutations: in 75 toxic thyroid nodules by denaturing gradient gel electrophoresis , 2001, Journal of Molecular Medicine.

[215]  G. Fontanini,et al.  N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. , 2000, Thyroid : official journal of the American Thyroid Association.

[216]  A. Sakamoto,et al.  Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin. , 2000, Pathology, research and practice.

[217]  S. Filetti,et al.  A Val 677 activating mutation of the thyrotropin receptor in a Hürthle cell thyroid carcinoma associated with thyrotoxicosis. , 1999, Thyroid : official journal of the American Thyroid Association.

[218]  S. Asa,et al.  Oncogene profile of papillary thyroid carcinoma. , 1999, Surgery.

[219]  M. Sobrinho-Simões,et al.  The common deletion of mitochondrial DNA is found in goiters and thyroid tumors with and without oxyphil cell change. , 1998, Ultrastructural pathology.

[220]  J. Blaydes,et al.  The influence of cell context on the selection pressure for p53 mutation in human cancer. , 1998, Carcinogenesis.

[221]  G. Vassart.  New pathophysiological mechanisms for hyperthyroidism. , 1997, Hormone research.

[222]  D. Wynford‐Thomas,et al.  Origin and progression of thyroid epithelial tumours: cellular and molecular mechanisms. , 1997, Hormone research.

[223]  J. Dumont,et al.  Thyroid autonomy : Mechanism and clinical effects , 1996 .

[224]  M. Pierotti,et al.  Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas. , 1994, European journal of cancer.

[225]  J. Fagin,et al.  High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. , 1993, The Journal of clinical investigation.

[226]  N. Lemoine,et al.  Activating point mutations of the gsp oncogene in human thyroid adenomas , 1991, Molecular carcinogenesis.

[227]  M. Sobrinho-Simões,et al.  The diagnostic value of flow cytometric DNA measurements in selected disorders of the human thyroid. , 1982, American journal of clinical pathology.

[228]  J. Fagin.  0888-8809/02/$15.00/0 Molecular Endocrinology 16(5):903–911 Printed in U.S.A. Copyright © 2002 by The Endocrine Society Minireview: Branded from the Start—Distinct Oncogenic Initiating Events May Determine Tumor Fate in the Thyroid , 2022 .

[229]  R. Paschke,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Clonal Origin of Toxic Thyroid Nodules with Constitutively Activating Thyrotropin Receptor Mutations* , 2022 .

[230]  C. Cheung,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Molecular Basis of , 2022 .